PROGEN — Prostatype Genomics AB Cashflow Statement
0.000.00%
- SEK3.23m
- SEK12.21m
- SEK1.36m
Annual cashflow statement for Prostatype Genomics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 June 30th | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 18 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Interim Report | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -8.55 | -17.4 | -15.6 | -29.1 | -41.4 |
Non-Cash Items | 0.713 | 0.776 | 0.088 | 1.9 | 2.47 |
Other Non-Cash Items | |||||
Changes in Working Capital | -1.8 | 1.92 | -0.537 | -0.511 | 9.82 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -9.63 | -14.7 | -16.1 | -27.7 | -29.1 |
Capital Expenditures | -3.26 | -3.26 | -2.5 | 0 | -8.56 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | — | — | -0.004 |
Purchase of Investments | |||||
Cash from Investing Activities | -3.26 | -3.26 | -2.5 | 0 | -8.57 |
Financing Cash Flow Items | 0 | 27.9 | 23.2 | 19.3 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 7.38 | 31.1 | 23 | 18.9 | 28.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -5.52 | 13.2 | 4.47 | -8.84 | -8.81 |